Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer

NCT02923921 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

567

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer

Interventions

BIOLOGICAL: Pegilodecakin
DRUG: FOLFOX

Sponsor

Eli Lilly and Company

Collaborators

[object Object]